Both medications, which are targeted therapies, are intended for treating NSCLC (NSCLC) and particularly NSCLC cases with EGFR gene mutations.Despite their similar modes of action, there are differences that are significant and can affect patient results.This article aims to provide a comprehensive review of the disparities between gefitinib and osimertinib, with an emphasis on their unique characteristics and considerations to take into account for their clinical application.Both medications inhibit the TK function of the EGFR enzyme, an activity vital to the proliferation and viability of cancerous cells.On the other hand,…
